$19.18
0.180.95%
Last update: Nov 11, 7:15 AM
NewAmsterdam Pharma Co NV (NAMS) Stock Price, Quote, News & History
NAMSNASDAQ
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.
You can purchase shares of NewAmsterdam Pharma Co (NASDAQ:NAMS) through any online brokerage.
Other companies in NewAmsterdam Pharma Co’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
NewAmsterdam Pharma Co has a consensus price target of $46.93.
The stock price for NewAmsterdam Pharma Co (NASDAQ: NAMS) is $19.25 last updated November 11, 2026 at 7:15 AM EST.
There are no upcoming dividends for NewAmsterdam Pharma Co.
NewAmsterdam Pharma Co does not have any upcoming earnings scheduled.
There is no upcoming split for NewAmsterdam Pharma Co.
NewAmsterdam Pharma Co is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib,...
